Welcome to 2024! SAGE is slowly yet surely approaching (March 11-14th 2024). All NITAG members are now allowed to listen in to the SAGE meeting. Please check the agenda and send an email to the SAGE secretariat to be added to the NITAG-SAGE mailing list if you are not yet part of it. 



"The STIKO is expanding its existing recommendation on the indication vaccination against meningococcal serogroup B (MenB) to include a recommendation on the MenB standard vaccination for infants and young children aged < 5 years. The MenB vaccine 4CMenB (Bexsero) available for this age group should be administered in a 2+1 schedule. Prophylactic administration of paracetamol is recommended to prevent fever or pain after MenB vaccination. As the Epidemiological Bulletin 3/2024 explains, the aim of the new vaccination recommendation is to reduce the morbidity of invasive MenB disease and the resulting consequences (hospitalization, severe complications, disability and death) in infants and young children. Due to the potentially severe symptoms, possible secondary damage and high mortality, the reduction of invasive MenB diseases is of great importance to the population despite their rarity."

The recommendation is based on a systematic review and meta analysis (some of the documents in the appendix are in English): https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2024/Ausgaben/03_24_Anhang.pdf?__blob=publicationFile).


COVID-19 vaccines:

"A large proportion of the population in Germany has now been vaccinated several times against COVID-19 and has had one or more SARS-CoV-2 infections. The hybrid immunity acquired as a result generally offers good protection against severe cases of COVID-19. Due to the acquired immune protection, infections with the currently circulating SARS-CoV-2 variants are predominantly mild in healthy people, although the risk of severe COVID-19 courses continues to increase steadily with age. STIKO has continuously adapted its COVID-19 vaccination recommendation since its initial publication in December 2020, taking into account new data and further vaccine approvals. The Epidemiological Bulletin 2/2024 publishes the updated COVID-19 vaccination recommendation and the associated scientific justification in order to review and, if necessary, complete the vaccination status. This shows, among other things, which groups of people should receive an annual COVID-19 booster vaccination in the fall in addition to basic immunity."

Starting in the spring of 2024, the following individuals who are at increased risk of severe illness from COVID-19 may receive an additional dose of XBB.1.5 COVID-19 vaccine:

  • Adults 65 years of age and older
  • Adult residents of long-term care homes and other congregate living settings for seniors
  • Individuals 6 months of age and older who are moderately to severely immunocompromised (due to underlying conditions or treatment)




Dates for your diary:

  • The next face-to-face GNN meeting will be in 28-30 April 2025
  • NITAG Recommendation